iBio Inc (IBIO)

[JPetroInc]

from Jewels021888 on Stockwits: "based on Tom's interview on The Hill along with his tweet from this morning - I think their proprietary adjuvant is IBIO's main focus. In a market saturated with 400 potential vaccine candidates, this is what sets IBIO aside from the rest. Tom has said in his interview that the 'adjuvant' has been underestimated. Think of mass production of something that can double efficacy, eliminate the need for multiple vaccinations, provide a continued higher immune response 40 days out. This 'adjuvant' is proprietary for IBIO and can be stockpiled for mass production for future pandemics and used in various companies potential vaccines. This is huge!!! Bigger than what we could have hoped for in fact - hopefully others can read between the lines.